SCHEMBL24254529

SCHEMBL24254529

CN(C)S(=O)(=O)c1ccc(NCc2ccccc2)c(NC(=O)Cc2ccc(Cl)c(Cl)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.53
GAA P10253 4/20 0.53
GFER P55789 2/20 0.53
KDM4E B2RXH2 1/20 0.53
HTT P42858 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 2/20 0.51
MAPT P10636 2/20 0.51
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
KCNJ6 P48051 2/20 0.48
KCNJ5 P48544 2/20 0.48
KCNJ3 P48549 2/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA5A P35218 1/20 0.48
CA7 P43166 1/20 0.48
CA5B Q9Y2D0 1/20 0.48
PKM P14618 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24254485 0.85 ALDH1A1 (0.60) ALDH1A1GAAGFERKDM4EHTT
SCHEMBL24254502 0.82 ALDH1A1 (0.66) ALDH1A1GAAHTTSMN1; SMN2LMNA
SCHEMBL24254497 0.81 ALDH1A1 (0.56) ALDH1A1GAAGFERKDM4EHTT
SCHEMBL24254505 0.77 LMNA (0.79) ALDH1A1HTTSMN1; SMN2LMNAMAPT
SCHEMBL24254564 0.77 ALDH1A1 (0.51) ALDH1A1HTTSMN1; SMN2LMNAMAPT
SCHEMBL24254499 0.76 LMNA (0.53) ALDH1A1HTTSMN1; SMN2LMNAMAPT
SCHEMBL24254500 0.75 ALDH1A1 (0.78) ALDH1A1GAAKDM4ESMN1; SMN2LMNA
SCHEMBL26188049 0.73 ALDH1A1 (0.64) ALDH1A1GAAKDM4ESMN1; SMN2LMNA
SCHEMBL24254509 0.72 ALDH1A1 (0.69) ALDH1A1GAAKDM4ESMN1; SMN2LMNA
SCHEMBL24254528 0.71 ALDH1A1 (0.50) ALDH1A1KDM4ESMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 ALDH1A1 1387/4885GAA 607/4885GFER 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.